From Yahoo Finance: 2025-05-16 08:57:00

Novo Nordisk’s CEO Lars Fruergaard Jorgensen steps down due to recent market challenges and share price decline following downgraded sales and profits forecast. Wegovy, a popular weight loss drug, faced competition from replica drugs, impacting sales. Competitor drug Zepbound showed more weight loss in a recent study, further affecting Novo Nordisk’s share price.

Read more: CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down in wake of share price drop